cbdMD, Inc. Q1 2026 Earnings Call Summary

Core Insights - The company achieved three consecutive quarters of sequential revenue growth, indicating positive trends in its core business [5] - A strategic multi-year reset was completed, focusing on reducing fixed costs and strengthening the balance sheet for sustainable growth [5] - The direct-to-consumer channel remains the primary revenue driver, accounting for approximately 72% of total revenue for the quarter [5] Financial Performance - The company reported a significant improvement in net loss per share, which decreased to $0.04 from $1.73 in the prior year, mainly due to the elimination of Series A preferred dividends [6] - Gross margin declined by 6% year-over-year, attributed to increased warehouse expenses and a shift in revenue mix towards the wholesale channel [5] Strategic Initiatives - The integration of the Bluebird Botanicals acquisition is a key focus, aiming to consolidate supply chain, marketing, and operations to realize synergies [5] - The company established a $20 million equity line of credit to capitalize on potential positive stock movements while minimizing dilution [5] - Participation in Medicare-related CBD programs is underway, with a pilot program set for April, favoring compliance-focused operators [5] Compliance and Capital Structure - The company regained full NYSE American continued listing compliance in early December, removing its previous temporary status [5] - A $2.25 million Series C preferred financing was completed in December to enhance liquidity and working capital positions [5] - The Bluebird Botanicals acquisition was structured with limited upfront equity and performance-based earn-outs to mitigate financial risk [5]